BR112021017996A2 - Inibidores de tyk2 e seus usos - Google Patents

Inibidores de tyk2 e seus usos

Info

Publication number
BR112021017996A2
BR112021017996A2 BR112021017996A BR112021017996A BR112021017996A2 BR 112021017996 A2 BR112021017996 A2 BR 112021017996A2 BR 112021017996 A BR112021017996 A BR 112021017996A BR 112021017996 A BR112021017996 A BR 112021017996A BR 112021017996 A2 BR112021017996 A2 BR 112021017996A2
Authority
BR
Brazil
Prior art keywords
disorder
tyk2
tyk2 inhibitors
inhibitors
mediated
Prior art date
Application number
BR112021017996A
Other languages
English (en)
Inventor
Bohan Jin
Gene Hung
Qing Dong
Original Assignee
Esker Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esker Therapeutics Inc filed Critical Esker Therapeutics Inc
Publication of BR112021017996A2 publication Critical patent/BR112021017996A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

nibidores de tyk2 e seus usos. são descritos, neste documento, compostos que são úteis no tratamento de um distúrbio mediado por tyk2. em algumas modalidades, o distúrbio mediado por tyk2 é um distúrbio autoimune, um distúrbio inflamatório, um distúrbio proliferativo, um distúrbio endócrino, um distúrbio neurológico ou um distúrbio associado a transplante.
BR112021017996A 2019-03-11 2020-03-10 Inibidores de tyk2 e seus usos BR112021017996A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962816698P 2019-03-11 2019-03-11
US201962835376P 2019-04-17 2019-04-17
US201962877741P 2019-07-23 2019-07-23
US201962931119P 2019-11-05 2019-11-05
PCT/US2020/021850 WO2020185755A1 (en) 2019-03-11 2020-03-10 Tyk2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112021017996A2 true BR112021017996A2 (pt) 2021-11-16

Family

ID=72427699

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017996A BR112021017996A2 (pt) 2019-03-11 2020-03-10 Inibidores de tyk2 e seus usos

Country Status (10)

Country Link
US (1) US20220177486A1 (pt)
EP (1) EP3938369A4 (pt)
JP (1) JP2022524974A (pt)
KR (1) KR20210141973A (pt)
CN (1) CN113811534A (pt)
AU (1) AU2020239026A1 (pt)
BR (1) BR112021017996A2 (pt)
CA (1) CA3132632A1 (pt)
IL (1) IL286248A (pt)
WO (1) WO2020185755A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202104017VA (en) 2018-10-22 2021-05-28 Esker Therapeutics Inc Tyk2 inhibitors and uses thereof
SG11202110523XA (en) * 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
WO2020233645A1 (zh) * 2019-05-21 2020-11-26 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
MX2022005563A (es) 2019-11-08 2022-08-19 Ventyx Biosciences Inc Ligandos de la pseudoquinasa tyk2.
EP4214215A1 (en) * 2020-09-16 2023-07-26 Alumis Inc. Tyk2 inhibitors and uses thereof
CN114591351B (zh) * 2020-12-03 2023-12-05 成都科岭源医药技术有限公司 一种多环化合物及其制备方法和用途
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof
WO2023178234A1 (en) * 2022-03-16 2023-09-21 Alumis Inc. Tyk2 inhibitors and uses thereof
WO2023178235A1 (en) * 2022-03-16 2023-09-21 Alumis Inc. Tyk2 inhibitors and uses thereof
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
UA121206C2 (uk) * 2014-01-24 2020-04-27 Турнінґ Поінт Терапьютикс, Інк. Діарильні макроцикли як модулятори протеїнкіназ
CN107735399B (zh) * 2015-07-02 2021-01-26 特普医药公司 作为蛋白质激酶的调节剂的手性二芳基大环
JOP20190092A1 (ar) * 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) * 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
MY201925A (en) * 2017-07-28 2024-03-23 Turning Point Therapeutics Inc Macrocyclic compounds and uses thereof
SG11202110523XA (en) * 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands

Also Published As

Publication number Publication date
EP3938369A4 (en) 2023-01-25
AU2020239026A1 (en) 2021-09-23
US20220177486A1 (en) 2022-06-09
KR20210141973A (ko) 2021-11-23
CA3132632A1 (en) 2020-09-17
IL286248A (en) 2021-10-31
WO2020185755A1 (en) 2020-09-17
JP2022524974A (ja) 2022-05-11
CN113811534A (zh) 2021-12-17
EP3938369A1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
BR112021017996A2 (pt) Inibidores de tyk2 e seus usos
CL2021000989A1 (es) Inhibidores tyk2 y uso de los mismos
CY1124730T1 (el) Αντισωματα εναντι pd-1 και χρησεις αυτων
DOP2017000199A (es) Receptores de antígeno quiméricos ant- dll3 y métodos de uso
BR112021022576A2 (pt) Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de uso dos mesmos
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
CY1120988T1 (el) Παρεμποδιστες διαρυλ κινασης
ECSP19086810A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
BR112018010673A8 (pt) moléculas de anticorpo para april e seus usos
BR112017023579A2 (pt) combinação de um anticorpo cd30xcd16 com um antagonista de pd-1 para terapia
CL2022001406A1 (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune.
EA201000219A1 (ru) Способ и композиция для лечения в-клеточных пролиферативных нарушений
CL2022002402A1 (es) Inhibidores del eif4e y sus usos
CL2021002656A1 (es) Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso.
CL2022001540A1 (es) Uso de inhibidores de atr en combinación con inhibidores de parp.
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
BR112021025544A2 (pt) Inibidores de autofagia de aminopirimidina amida e métodos de uso dos mesmos
BR112017023855A2 (pt) o uso de estimulantes de sgc, ativadores de scg, em separado e combinações com inibidores de pde5 para o tratamento de úlceras digitais (du) concomitantes à esclerose múltipla (ssc)
BR112022011902A2 (pt) Terapias de combinação
CL2020003118A1 (es) Régimen de dosificación para el tratamiento de trastornos relacionados con pi3k.
CL2020002165A1 (es) Uso de tradipitant para tratar la cinetosis.
CL2018003417A1 (es) Nuevos compuestos.
CR20180465A (es) Composiciones y métodos para tratar artritis reumatoide
CL2018003838S1 (es) Botella.